Gilead Sciences Debt/Equity Ratio 2010-2024 | GILD

Gilead Sciences debt/equity ratio for the quarter ending June 30, 2024 was 1.18.

  • Gilead Sciences average debt/equity ratio for 2023 was 1.07, a 12.3% increase from 2022.
  • Gilead Sciences average debt/equity ratio for 2022 was 1.22, a 10.29% decline from 2021.
  • Gilead Sciences average debt/equity ratio for 2021 was 1.36, a 1.45% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

Gilead Sciences Debt/Equity Ratio 2010-2024 | GILD

  • Gilead Sciences average debt/equity ratio for 2023 was 1.07, a 12.3% increase from 2022.
  • Gilead Sciences average debt/equity ratio for 2022 was 1.22, a 10.29% decline from 2021.
  • Gilead Sciences average debt/equity ratio for 2021 was 1.36, a 1.45% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$178.8B
Regeneron Pharmaceuticals (REGN)$126.4B
Vertex Pharmaceuticals (VRTX)$124.2B
Bristol Myers Squibb (BMY)$100.3B
CSL (CSLLY)$97.4B
GSK (GSK)$88.2B
Alnylam Pharmaceuticals (ALNY)$35.2B
Argenex SE (ARGX)$31.2B
BioNTech SE (BNTX)$29.7B
Biogen (BIIB)$28.9B
Moderna (MRNA)$27.7B
Illumina (ILMN)$20.7B
BeiGene (BGNE)$19.2B
Genmab (GMAB)$17.5B
BioMarin Pharmaceutical (BMRN)$13.4B
Vaxcyte (PCVX)$13B
Incyte (INCY)$12.8B
Insmed (INSM)$12.6B
Exact Sciences (EXAS)$12.6B
Sarepta Therapeutics (SRPT)$12B
Bio-Techne Corp (TECH)$11.9B
QIAGEN (QGEN)$10.4B
Legend Biotech (LEGN)$9.3B
Bio-Rad Laboratories (BIO.B)$9.1B
Roivant Sciences (ROIV)$8.9B
Ascendis Pharma (ASND)$8.5B
Intra-Cellular Therapies (ITCI)$7.9B
Exelixis (EXEL)$7.9B
Halozyme Therapeutics (HALO)$7.8B
Repligen (RGEN)$7.6B